NCT04629872

Fingolimod in Endovascular Treatment of Ischemic Stroke

Combinating Fingolimod With Endovascular Treatment in Acute Ischemic Stroke

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Ning Wang, MD., PhD. · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with acute ischemic stroke as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. This study aim to determine whether fingolimod enhance the action of endovascular treatment for acute ischemic stroke

Conditions

• Stroke Inflammation

Interventions

Type	Name	Description
DRUG	Fingolimod	Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.

Timeline

• Start date: 2020-11-12
• Primary completion: 2022-12-30
• Completion: 2023-12-30
• First posted: 2020-11-16
• Last updated: 2022-04-13

Locations

1 site across 1 country: China